Xinmao Song1, Huanyu He2, Yi Zhu1, Shengzi Wang1, Jie Wang3, Weifang Wang1, Yi Li2. 1. Department of Radiation Oncology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, China. 2. Department of Oncology, 920th Hospital of Joint Logistics Support Force, Kunming, China. 3. Department of E.N.T., Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, China.
Abstract
OBJECTIVES: Tumors of the lacrimal sac are rare and life-threatening. Because of their rarity, no extensive clinical data on their management and prognosis exist. We investigated the application of definitive radiation therapy and its outcome in patients with lacrimal sac squamous cell carcinoma (LSSCC). METHODS: We retrospectively studied 17 patients with LSSCC at a single institution between 2003 and 2017. All the patients were treated with definitive radiotherapy, and 11 patients were delivered with cisplatin-based chemotherapy. The patients' clinical records were reviewed for symptoms, pathological types, the volume and dosimetry of the tumors and their adjacent structures, radiation coverage of lymph node drainage areas, treatment outcomes, and complications from definitive radiotherapy. RESULTS: Median follow-up was 38.9 months, and age at diagnosis was 48 years.The 2-year and 5-year overall survival, progression-free survival, locoregional control, and disease metastasis-free survival rates were 94.1 and 84.7%, 88.2 and 73.5%, 93.8%, 94.1, and 78.4%, respectively. A total dose of 6600-7000 cGy was prescribed to the tumor. Levels Ⅰb, Ⅶa, Ⅷ, and Ⅸ were covered with the clinical target volume regardless of lymph involvement. Acute Grade 3 radiation dermatitis occurred in seven patients (17.6%), but no acute Grade 4 or Grade 5 toxicity of any type occurred. Seven (41.2%, 7/17) of the treated eyes had moderated vision impairments; 17.6% (3/17) of patients developed cataracts, and glaucoma and radiation retinopathy were found in 5.9% (1/17) of patients. CONCLUSIONS: Definitive radiotherapy could be a treatment option for those who refuse surgery or have unresectable LSSCC. ADVANCES IN KNOWLEDGE: Radiation alone is a treatment option for LSSCC.
OBJECTIVES: Tumors of the lacrimal sac are rare and life-threatening. Because of their rarity, no extensive clinical data on their management and prognosis exist. We investigated the application of definitive radiation therapy and its outcome in patients with lacrimal sac squamous cell carcinoma (LSSCC). METHODS: We retrospectively studied 17 patients with LSSCC at a single institution between 2003 and 2017. All the patients were treated with definitive radiotherapy, and 11 patients were delivered with cisplatin-based chemotherapy. The patients' clinical records were reviewed for symptoms, pathological types, the volume and dosimetry of the tumors and their adjacent structures, radiation coverage of lymph node drainage areas, treatment outcomes, and complications from definitive radiotherapy. RESULTS: Median follow-up was 38.9 months, and age at diagnosis was 48 years.The 2-year and 5-year overall survival, progression-free survival, locoregional control, and disease metastasis-free survival rates were 94.1 and 84.7%, 88.2 and 73.5%, 93.8%, 94.1, and 78.4%, respectively. A total dose of 6600-7000 cGy was prescribed to the tumor. Levels Ⅰb, Ⅶa, Ⅷ, and Ⅸ were covered with the clinical target volume regardless of lymph involvement. Acute Grade 3 radiation dermatitis occurred in seven patients (17.6%), but no acute Grade 4 or Grade 5 toxicity of any type occurred. Seven (41.2%, 7/17) of the treated eyes had moderated vision impairments; 17.6% (3/17) of patients developed cataracts, and glaucoma and radiation retinopathy were found in 5.9% (1/17) of patients. CONCLUSIONS: Definitive radiotherapy could be a treatment option for those who refuse surgery or have unresectable LSSCC. ADVANCES IN KNOWLEDGE: Radiation alone is a treatment option for LSSCC.
Authors: Vincent Grégoire; Kian Ang; Wilfried Budach; Cai Grau; Marc Hamoir; Johannes A Langendijk; Anne Lee; Quynh-Thu Le; Philippe Maingon; Chris Nutting; Brian O'Sullivan; Sandro V Porceddu; Benoit Lengele Journal: Radiother Oncol Date: 2013-10-31 Impact factor: 6.280
Authors: Charles Mayo; Mary K Martel; Lawrence B Marks; John Flickinger; Jiho Nam; John Kirkpatrick Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Xinmao Song; Shengzi Wang; Jie Wang; Weifang Wang; Shuyi Wang; Gang Yang; Ji Li; Yi Zhu; Fu Chen; Wenjia Zhu Journal: Head Neck Date: 2019-01-10 Impact factor: 3.147
Authors: Antonio Ramos; Carmen Del Pozo; Ana Chinchurreta; Fernando García; Mercedes Lorenzo; Saturnino Gismero Journal: Arq Bras Oftalmol Date: 2016 Sep-Oct Impact factor: 0.872
Authors: Puyao C Li; Norbert J Liebsch; Andrzej Niemierko; Drosoula Giantsoudi; Simmons Lessell; Barbara C Fullerton; Judith Adams; Helen A Shih Journal: Radiother Oncol Date: 2018-12-31 Impact factor: 6.280
Authors: Heath D Skinner; Adam S Garden; David I Rosenthal; K Kian Ang; William H Morrison; Bita Esmaeli; Chelsea C Pinnix; Steven J Frank Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Emma B Holliday; Bita Esmaeli; Jamie Pinckard; Adam S Garden; David I Rosenthal; William H Morrison; Merrill S Kies; G Brandon Gunn; C David Fuller; Jack Phan; Beth M Beadle; Xiarong Ronald Zhu; Xiaodong Zhang; Steven J Frank Journal: Int J Radiat Oncol Biol Phys Date: 2015-08-07 Impact factor: 7.038